Misplaced Pages

Human anti-chimeric antibody

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Human anti-chimeric antibody" – news · newspapers · books · scholar · JSTOR (January 2015) (Learn how and when to remove this message)

The human anti-chimeric antibody (HACA) can develop in patients undergoing autoimmune disease therapy with the drug infliximab. This drug can cause the patient to develop antibodies to the medicine itself, which are termed HACAs. The incidence of developing these antibodies is highest in patients receiving intermittent therapy with infliximab, and lowest in patient receiving continuous therapy and concomitant immunosuppressive therapy. Some suggest that the presence of these antibodies causes a decrease in efficacy of infliximab and increased risk of infusion reactions.

References

Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Lymphocytic adaptive immune system and complement
Lymphoid
Antigens
Antibodies
Immunity vs.
tolerance
Immunogenetics
Lymphocytes
Substances
Globular proteins
Serum globulins
Alpha globulins
serpins:
carrier proteins:
other:
Beta globulins
carrier proteins:
other:
Gamma globulin
Other
Other globulins
Albumins
Egg white
Serum albumin
Other
Antibodies
Main types
Chains
Autoantibodies
Anti-nuclear antibody
Anti-mitochondrial antibody
Anti-cytoplasm antibody
Cell membrane
Extracellular
Multiple locations
Categories: